Unlocking Relief: Exploring the Booming Opioid-Induced Constipation (OIC) Treatment Market and its Promising Future

Opioid-Induced Constipation (OIC) Treatment Market was valued at $1105.71 million in 2021, and is projected to reach $1785.01 million by 2031, growing at a CAGR of 4.9% from 2022 to 2031.

The Opioid-Induced Constipation (OIC) treatment market refers to the pharmaceutical products and therapies used to manage constipation caused by the use of opioid medications. Opioids are commonly prescribed for pain management, but they can have the side effect of slowing down bowel movements, leading to constipation.

The OIC treatment market has experienced significant growth in recent years due to the increasing use of opioids for chronic pain management. Constipation is a common and distressing side effect of opioid therapy, affecting a substantial number of patients.

Several pharmaceutical companies have developed and marketed medications specifically designed to treat OIC. These medications belong to a class of drugs known as peripherally acting mu-opioid receptor antagonists (PAMORAs). PAMORAs work by blocking the opioid receptors in the gut, thereby relieving constipation while preserving the pain-relieving effects of opioids.

 Some of the commonly prescribed OIC treatment medications include:

Movantik (naloxegol): Developed by AstraZeneca, Movantik was the first FDA-approved medication specifically indicated for the treatment of OIC in adults with chronic non-cancer pain.

Amitiza (lubiprostone): While originally approved for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation, Amitiza has also been studied and used off-label for OIC.

Symproic (naldemedine): Manufactured by Shionogi Inc., Symproic is another PAMORA approved for the treatment of OIC in adults with chronic non-cancer pain.

It’s important to note that treatment for OIC may also involve non-pharmacological approaches, such as dietary modifications, increased physical activity, and the use of laxatives or stool softeners.

Get Free Exclusive PDF Sample Copy of This Research Report https://stringentdatalytics.com/sample-request/opioid-induced-constipation-(oic)-treatment-market/1906/

Market Segmentations:

Global Opioid-Induced Constipation (OIC) Treatment Market: By Company
• GlaxoSmithKline
• AstraZeneca
• Pfizer
• S.L.A. Pharma
• AIKO Biotechnology
• Cubist Pharmaceuticals
• Salix Pharmaceuticals
• Takeda Pharmaceutical

Market: By Type
• Oral
• Parenteral (Subcutaneous Injection)

Market: By Application
• Drug Store
• Independent Pharmacies
• Hospital Pharmacies

 Market: Regional Analysis
All the regional segmentation has been studied based on recent and future trends, and the market is forecasted throughout the prediction period. The countries covered in the regional analysis of the Global Opioid-Induced Constipation (OIC) Treatment market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Russia, Italy, Spain, Turkey, Netherlands, Switzerland, Belgium, and Rest of Europe in Europe, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, China, Japan, India, South Korea, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), and Argentina, Brazil, and Rest of South America as part of South America.

Reasons to Purchase this Market Report:

• The competitive environment includes the proportions of important players, recent innovations, and strategy.
• Companies with extensive product offerings, pertinent financial data, recent advancements, SWOT analyses, and player tactics.
• Quantitative, qualitative, value (in USD million), and volume (in units million) data are among the segments and sub-segments.
• The research contains a wealth of data, including market dynamics and opportunities throughout the forecast period.
• Data at the regional, sub-regional, and national levels also provides information on the market’s supply and demand dynamics.

Access Full Report Here: https://stringentdatalytics.com/reports/opioid-induced-constipation-(oic)-treatment-market/1906/

 Frequently Asked Questions

• What is the current size and growth rate of the Opioid-Induced Constipation (OIC) treatment market?
• What is the Opioid-Induced Constipation (OIC) treatment market?
• What are the key factors driving the growth of the OIC treatment market?
• What are the major treatment options available for OIC?
• What are the opportunities in the OIC treatment market?

About Stringent Datalytics

Stringent Datalytics offers both custom and syndicated market research reports. Custom market research reports are tailored to a specific client’s needs and requirements. These reports provide unique insights into a particular industry or market segment and can help businesses make informed decisions about their strategies and operations.

Syndicated market research reports, on the other hand, are pre-existing reports that are available for purchase by multiple clients. These reports are often produced on a regular basis, such as annually or quarterly, and cover a broad range of industries and market segments. Syndicated reports provide clients with insights into industry trends, market sizes, and competitive landscapes. By offering both custom and syndicated reports, Stringent Datalytics can provide clients with a range of market research solutions that can be customized to their specific needs.

Contact Us

Stringent Datalytics

Contact No- 91-9763384149

Visit Our More Bloghttps://www.linkedin.com/pulse/dermatology-treatment-devices-market-statistics-growth-phadatare